Welcome to PharmTx
Our Story
Features and Benefits
Our Concept
We started pHarmTx with a simple goal in mind: to create a company that transforms the pain market by developing potent analgesics without the drastic and sometimes fatal side effects that make it difficult to deliver safe and effective medications for pain
Our Concept
Features and Benefits
Our Concept
At pHarmTx, we are taking advantage of the acidic microenvironment caused by inflammation during episodic pain. Our proprietary compound is activated only at lower pH levels and is otherwise inert at normal physiological conditions throughout the body.
Features and Benefits
Features and Benefits
Features and Benefits
By negating central and peripheral side effects, our targeted pH activation approach diverged the analgesic benefit away from profound side effects like respiratory depression, addiction, bradycardia, sedation, tolerance and constipation. We believe this superior side effect profile and powerful pain fighting MOA combines to give first in class potent pain killing medicine.
Our Founders
Dr. Christoph Stein
Dr. Christoph Stein
Dr. Christoph Stein
Anesthesiologist, Co-Founder
Clinician Scientist
Charité University, Germany.
Dr. Stein has held numerous positions at leading institutions in the United States including Johns Hopkins, and developed the novel pharmacodynamics concept for analgesics for pHarmTx
Dr. Stephen Vanner
Dr. Christoph Stein
Dr. Christoph Stein
MSc FRCPC FCAHS FCAG
Gastroenterologist, Co-Founder
Clinician Scientist
Queen's University, Canada
Dr. Vanner has led an internationally recognized research program for over 30 years. He has held numerous local, national and international leadership positions and leads the translational research program at pHarmTx
Dr. John Nesbitt
Dr. Christoph Stein
Dr. John Nesbitt
Advisor
Clinician
Calgary, Alberta
Dr. Nesbitt is a family physician in
Calgary, Alberta and has participated in numerous start-up companies in the medical device space over the last 25 years. At pHarmTx he is responsible for sourcing and securing non-dilutive financing, and led the seed round financing in 2025
Experienced Management
Piet Wigerinck, Drug Development
Piet Wigerinck, Drug Development
Piet Wigerinck, Drug Development
Former CSO at Galapagos, guided 30+ compounds into the clinic,
4 approved drugs, 30 years experience drug hunting. Based
in Belgium, Europe
John Vittoria, CFO
Piet Wigerinck, Drug Development
Piet Wigerinck, Drug Development
Former CFO John Vittoria Harmony Pharmaceuticals, 30 years finance experience in large and small public and private companies. Based in New York, USA.
Mark Steedman, CEO
Piet Wigerinck, Drug Development
Mark Steedman, CEO
Serial life sciences entrepreneur,
20 years experience in raising
capital and dealmaking. Based in Toronto, Canada